Updated clinical guidance from the National Lipid Association provides evidence-based strategies for the diagnosis, screening, and management of familial hypercholesterolemia (global prevalence 1 in 311).
This expert consensus updates the 2011 NLA guidance on familial hypercholesterolemia, emphasizing genetic testing, cascade screening, and intensified LDL-C lowering with newer therapies.
Familial hypercholesterolemia (FH) is a common genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol (LDL-C), leading to a high risk of early onset atherosclerotic cardiovascular disease (ASCVD). This document provides an update to the National Lipid Association's 2011 clinical guidance, summarizing the remarkable progress in the field. With a global prevalence of approximately 1 in 311, FH remains severely underdiagnosed. This guidance reviews current diagnostic criteria, including the expanding role of genetic testing to complement diagnosis and to facilitate cascade screening, and emphasizes a thorough differential diagnosis. It provides recommendations for universal pediatric screening and systematic cascade screening in families to improve detection. Management strategies include intensified LDL-C treatment goals for both primary and secondary prevention of ASCVD. A stepwise approach to optimal therapy is outlined, beginning with lifestyle interventions and pharmacotherapy with maximally tolerated statins and ezetimibe. This update incorporates newer agents, including proprotein convertase subtilisin/kexin type 9 inhibitors and bempedoic acid. Additional therapies, such as lomitapide and evinacumab for homozygous FH and lipoprotein apheresis for heterozygous and homozygous FH, are discussed. Further topics include cardiovascular imaging for risk stratification, management in specific populations and circumstances, such as planning for and during pregnancy and in pediatrics, and recognition of health disparities. This guidance equips clinicians with evidence-based strategies to improve the identification and care of patients with FH, ultimately reducing the high morbidity and mortality associated with this condition.
“This comprehensive statement synthesizes critical knowledge on FCS, a severe genetic disorder causing extremely high triglycerides and a life-threatening risk of recurrent acute pancreatitis. The expert opinion highlights the challenges of diagnosis, the necessity of a lifelong ultra-low-fat diet (< 15% of energy), and the promise of new therapies targeting apolipoprotein C-III (APOC3) like olezarsen (recently FDA-approved) and plozasiran (under FDA review), which offer hope for reducing triglycerides and pancreatitis risk in FCS patients.”
Ahmad et al. (Thu,) conducted a review in Familial hypercholesterolemia. Clinical guidance was evaluated. Updated clinical guidance from the National Lipid Association provides evidence-based strategies for the diagnosis, screening, and management of familial hypercholesterolemia (global prevalence 1 in 311).